We investigated the role of angiotensin (Ang) II in maintaining blood pressure (BP) by administering a small dose of candesartan, an Ang II type 1 receptor antagonist, in postmenopausal women receiving long-term hormone replacement therapy (HRT).
T he renin-angiotensin-aldosterone system plays a central role in the regulation of blood pressure (BP) and in the pathophysiology of hypertension. 1, 2 Angiotensin (Ang) II, the primary effector hormone of the reninangiotensin-aldosterone system and one of the most potent endogenous vasoconstrictive peptides, is formed from Ang I by the action of angiotensin-converting enzyme (ACE). 3 In addition to this conversion by ACE, Ang I is converted to Ang II locally by specific serine proteases in tissues, whereas ACE plays only a minor role in this pathway of local Ang II formation. 2 In humans, Ang II receptors are differentiated into two subtypes: Ang II type 1 (AT 1 ) receptors and Ang II type 2 (AT 2 ) receptors. 2, 3 AT 1 receptor signaling is thought to mediate vasoconstriction, aldosterone secretion, cardiomyocyte hypertrophy, the proliferation of fibroblasts, interstitial collagen deposition, catecholamine release, and the progression of left ventricular remodeling. 4 The AT 2 receptor is thought to have effects that are opposite those of the AT 1 receptor and has been shown to mediate vasodilation 5 and to suppress myocardial hypertrophy, 6 fibroblast proliferation, 6 and left ventricular remodeling after myocardial infarction. 7 The development of a novel class of compounds, non-peptide AT 1 receptor antagonists, has enabled a more specific method of blocking the renin-angiotensin-aldosterone system, compared with the use of ACE inhibitors, for the treatment of hypertension. 8 Candesartan is a potent, long-acting, selective AT 1 receptor blocker that is well tolerated and effective using a once-daily dosing regimen in hypertensive patients. 9 The inhibitory effects of candesartan on the pressor effects of intravenously administered Ang II have been shown to be dose related and long lasting in healthy male volunteers.
10
The renin-angiotensin-aldosterone system has been reported to be modulated by hormone replacement therapy (HRT), without causing an increase in BP in either hypertensive or normotensive postmenopausal women. [11] [12] [13] [14] [15] We previously reported that long-term HRT of Ͼ6 months duration in postmenopausal women with essential hypertension or normotension increased the circulating plasma bradykinin concentrations in these women and concomitantly decreased their serum ACE activity without causing a decline in BP. [13] [14] [15] We also found that HRT increased the plasma concentrations of Ang II without increasing BP, despite a reduction in serum ACE activity in postmenopausal women.
14 These peptides could contribute to the maintenance of BP at normal levels in postmenopausal women treated with HRT, as bradykinin and Ang II are potent endogenous vasorelaxant and vasoconstrictive peptides, respectively. However, whether Ang II contributes to the maintenance of BP in postmenopausal women treated with HRT has not been established. Therefore, this study was designed to investigate the effect of Ang II on BP in postmenopausal women treated with long-term HRT by blocking endogenous Ang II using an Ang II antagonist, candesartan.
Methods

Subjects
A total of 26 healthy normotensive (supine BP Ͻ140/ 90 mm Hg) postmenopausal women (49 to 63 years of age, mean 58.3 Ϯ 1.1 years) with no evidence of gynecologic disorders volunteered to participate in this study ( Table 1) . The subjects were divided into two groups: postmenopausal women who were receiving HRT (HRT group; n ϭ 13) and postmenopausal women who had not received HRT (control group; n ϭ 13). The 13 postmenopausal women receiving HRT had been taking an oral daily dose of 0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate for Ͼ1 year. The control subjects had serum concentrations of estradiol (E 2 ) Ͻ20 pg/mL and serum concentrations of follicle-stimulating hormone (FSH) Ͼ40 mIU/mL. All subjects in both groups had been postmenopausal for 2 to 10 years. None of the subjects smoked or had a history of hypertension, thyroid disease, liver disease, diabetes mellitus, or cardiovascular disease, and none were taking any medication known to influence the renin-angiotensin-aldosterone system, BP, or heart rate (HR). The study protocol was approved by the Institutional Committee on Human Research of the Cardiovascular Hospital of Central Japan. Informed consent was obtained from each individual before enrollment in the study.
Protocol
Alcohol, caffeine, and HRT were prohibited for 12 h before and during the study. Subjects were instructed to arrive at the Cardiovascular Hospital of Central Japan before 8 AM after having fasted overnight. The effect of candesartan, an antagonist of the AT 1 receptor, on BP was examined in 13 normotensive postmenopausal women receiving HRT and 13 normotensive postmenopausal women not receiving HRT. After all subjects had rested in a supine position for 1 h to allow their BP, HR, and hormone concentrations to reach a baseline value, a single oral dose of 2 mg of candesartan with 50 mL of water was administered to each patient at 9 AM. The subjects were then asked to remain in the same position for 6 h after the drug administration. After the subjects had rested for more than 30 min in a supine position, their BP and HR (average of five measurements performed every 2 min) were monitored at defined intervals (before and 1, 2, 3, 4, 5, and 6 h after dosing) while the patients were supine. Blood samples were collected at baseline and at 4 h after drug administration under the same conditions to determine the plasma renin activity (PRA), serum ACE activity, and bradykinin, Ang I, Ang II, aldosterone, epinephrine, norepinephrine, and candesartan concentrations.
Drugs
Candesartan was provided by the Pharmaceutical Development Division, Takeda Chemical Industries, Ltd.
(Osaka, Japan).
Physical Examination
Blood pressure was recorded using an automatic BP recorder (USM-700G, Ueda Co., Tokyo, Japan). This device uses an oscillometer to determine the systolic BP (SBP) and diastolic BP (DBP). The arm cuff was automatically inflated by a pump and the BP was digitally recorded. The arm cuff (12 cm in length, standard adult size) was positioned in the middle of the non-dominant arm, covering the brachial artery above the antecubital fossa. The correct positioning of the cuff was confirmed when three SBP and DBP values were concordant (Ϯ5 mm Hg) with those obtained on the opposite arm using a standard sphygmomanometer.
Assays
Blood samples were immediately centrifuged at 3500 rpm for 10 min at 4°C and stored at Ϫ80°C until the time of assay. Serum total cholesterol and triglyceride concentrations were determined using enzymatic methods (Medca Japan, Kohnosu, Japan). The serum concentration of high-density lipoprotein (HDL) cholesterol was determined electrophoretically using the HDL Cholesterol Supply Kit (Helena Laboratory, Beaumont, TX). The concentration of low-density lipoprotein (LDL) cholesterol was calculated according to the Friedewald formula. 16 The serum concentrations of FSH and E 2 were measured using radioimmunoassays. The PRA and the plasma Ang I, Ang II, and aldosterone concentrations were determined using radioimmunoassays as previously reported.
14 The plasma bradykinin concentration was measured using a radioimmunoassay as previously described. 17 Serum ACE activity was determined by colorimetry according to the method of Kasahara et al. 18 Plasma epinephrine and norepinephrine concentrations were quantified in duplicate using high-performance liquid chromatography. Serum candesartan concentrations were measured by a specific and sensitive reverse-phase pressure liquid chromatographic method, using ultraviolet detection for candesartan and candesartan cilexetil and fluorescence detection for the inactive compound, CV-15959, at the Takeda Analytical Research Laboratories, Ltd. (Osaka, Japan).
Statistical Analysis
All values were expressed as the mean Ϯ SEM. A Student t test was used to analyze the differences in values between the HRT and control groups. A Student paired t test was used to analyze the differences between the values recorded at baseline and those recorded 4 h later. A two-way analysis of variance was used to compare the BP and HR measurements at baseline and 1, 2, 3, 4, 5, and 6 h after the administration of candesartan between the HRT and control groups. A value of P Ͻ .05 was considered to be statistically significant.
Results
Characteristics of the study population are summarized in Table 1 . Before treatment, no significant differences in age, BMI, BP, HR, total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations were seen between the HRT group and the control group.
The changes in SBP, DBP, mean BP (MBP), and HR after the administration of candesartan in the two groups are presented in Fig. 1 . In the HRT group, candesartan significantly decreased the SBP at 2 to 6 h and the DBP and MBP at 1 to 6 h compared with baseline levels. Similarly, in the control group, SBP, DBP, and MBP were significantly lower at 2 to 5 h, 2 to 6 h, and 1 to 6 h, respectively, compared with baseline levels. The SBP, DBP, and MBP were significantly lower in the HRT group than in the control group at 4 h. In both groups, the HR was significantly higher at 3 to 6 h compared with baseline levels. No significant differences in HR were observed between the HRT and control groups.
Baseline PRA and Ang I, Ang II, and bradykinin concentrations were significantly higher and the ACE activity was lower in the HRT group than in the control group. However, no significant differences in aldosterone, epinephrine, norepinephrine, and candesartan baseline concentrations were observed between the HRT and control groups ( Table 2 ). In the HRT group, candesartan significantly increased PRA and Ang I, Ang II, and candesartan concentrations at 4 h after administration and significantly decreased bradykinin concentrations, compared with baseline. However, ACE activity and aldosterone, epinephrine, and norepinephrine concentrations showed no significant change 4 h after administration of candesartan. In the control group, candesartan significantly increased PRA and epinephrine, norepinephrine, and candesartan concentrations and decreased the aldosterone concentration at 4 h after administration compared with the baseline. The ACE activity and Ang I, Ang II, and bradykinin concentrations showed no significant changes 4 h after the administration of candesartan. At 4 h after candesartan administration, the Ang I and Ang II concentrations were significantly higher and ACE activity was lower in the HRT group than in the control group, but no significant differences in any other parameters were observed between the HRT and control groups. 
Discussion
The present study shows that candesartan lowered BP in both the HRT and the control groups. However, candesartan lowered BP to a greater extent in the HRT group than in the control group, although no differences in HR between the HRT and the control groups were observed. Additionally, candesartan increased the PRA and the Ang I and Ang II concentrations and decreased bradykinin concentrations in the HRT group. In the control group, candesartan increased PRA but did not change Ang I, Ang II, and bradykinin concentrations. Epinephrine and norepinephrine concentrations were increased and aldosterone concentration was decreased by candesartan in the control group but not in the HRT group.
Recent studies have demonstrated that estrogen therapy induces the down-regulation of AT 1 receptor mRNA expression in the vascular smooth-muscle cells of aortas from ovariectomized rats 19 and that estrogen administration increases renal AT 2 receptor mRNA in ovariectomized mice. 20 Barber et al 21 reported that in spontaneously hypertensive rats, AT 2 receptor activation facilitates the depressor response caused by the AT 1 receptor antagonist candesartan. The AT 2 receptor has also been reported to cause vasodilation. 5 When Ang II is elevated by the administration of estrogen plus candesartan, the excess Ang II that has not combined with the available AT 1 receptors likely combines with AT 2 receptors. In addition, KellerWood et al 22 demonstrated that HR responses to hypotension are decreased in pregnant ewes, consistent with the observation that baroreflex responses are decreased in pregnant rats. In rats, estrogen also modulates autonomic nerve function, suggesting that estrogen at the central and peripheral levels tends to suppress sympathetic tone while increasing parasympathetic tone in the cardiovascular system. 23 Thus, HRT may inhibit the sympathetic nervous system, resulting in lowering of BP in postmenopausal women receiving this therapy. Therefore, candesartan may lower BP to a greater extent in the HRT-treated women, in whom the sympathetic nervous system is depressed by estrogen, than in the control group of women, as the increase in HR caused by candesartan was similar in both groups.
Interactions between estrogens and various components of the renin-angiotensin-aldosterone system have long been reported. Substantial evidence suggests that estrogens have a significant impact on the renin-angiotensinaldosterone system. Schunkert et al 24 reported that oral or transdermal estrogen augments serum concentrations of angiotensinogen, thereby decreasing plasma renin levels and ACE activity, but does not alter aldosterone concen- trations. Some previous studies demonstrated that orally administered conjugated estrogen increases PRA. 14, 25 Moreover, orally administered conjugated estrogen or orally administered estradiol reduces tissue and circulating ACE activities. [11] [12] [13] [14] [15] 24, 25 Conjugated estrogen increases the plasma Ang I concentration 14, 25 and increases 14 or has no effect on Ang II 25 and aldosterone concentrations. 14, 24 These observations are similar to those in the present study, in which baseline PRA and Ang I, Ang II, and bradykinin concentrations were significantly higher in the HRT group than in the control group, whereas the baseline aldosterone concentration was similar in both groups.
In the present study, candesartan increased PRA and the Ang I and Ang II concentrations and decreased the bradykinin concentration in the HRT group. On the other hand, in the control group, candesartan did not change the ACE, Ang I, Ang II, and bradykinin concentrations, despite an increase in PRA. This difference might be caused by the larger decrease in BP in the HRT group than in the control group.
Candesartan increased epinephrine and norepinephrine concentrations and decreased aldosterone concentrations in the control group but not in the HRT group. The effects of candesartan on catecholamines, however, were less in the HRT group than in the control group. It may be noteworthy that estrogen has been shown to interfere with catecholamine synthesis 26, 27 and to decrease circulating concentrations of norepinephrine and epinephrine as well as HR. 28, 29 Therefore, the above observation may be caused by the depressed sympathetic nervous system in the HRT group.
Candesartan has dose-related and long-lasting inhibitory effects on BP and on the renin-angiotensin-aldosterone system. Delacretaz et al 10 showed that a single dose of 2, 4, or 8 mg induced a dose-related inhibition of the response to intravenous bolus injections of Ang II and significantly increased PRA and the Ang II concentration in healthy normotensive volunteers. The peak effect was achieved 4 to 8 h after treatment. These findings are consistent with those of the present study in which the ingestion of a 2-mg dose of candesartan produced a maximal decrease in the SBP and DBP at 4 h after administration in both the HRT and control groups. In the present study, however, Ang I and Ang II concentrations in the control group tended to increase 4 h after treatment with the 2-mg dose of candesartan, although the increase was not significant. The lack of significance in the present data may have been caused by the small number of subjects enrolled in the control group or by the relatively small dose of candesartan.
In conclusion, the present data suggest that Ang II plays an important role in maintaining BP in normotensive postmenopausal women receiving HRT and that the maintenance of BP may be dependent on the balance between the hypertensive effect of Ang II and the hypotensive effect of bradykinin. Because AT 1 receptor antagonists have beneficial effects on the cardiovascular system and a greater hypotensive effect on postmenopausal women receiving HRT than on postmenopausal women not receiving HRT, we propose that AT 1 receptor antagonists might be beneficial to postmenopausal women with hypertension. Further studies are needed to confirm this possibility.
